ERMIUM THERAPEUTICS
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
ERMIUM THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.ermium.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
13.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Apache
Similar Organizations
ARCEDI Biotech
ARCEDI Biotech is a biotech company, develops technologies and methods for detecting and diagnosing rare cancer cells.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Ermium Therapeutics
Kurma Partners
Kurma Partners investment in Series A - Ermium Therapeutics
Eurazeo
Eurazeo investment in Venture Round - Ermium Therapeutics
Erganeo
Erganeo investment in Series A - Ermium Therapeutics
Idinvest Partners
Idinvest Partners investment in Series A - Ermium Therapeutics
Kurma Partners
Kurma Partners investment in Series A - Ermium Therapeutics
Domain Therapeutics
Domain Therapeutics investment in Series A - Ermium Therapeutics
Official Site Inspections
http://www.ermium.com Semrush global rank: 4.95 M Semrush visits lastest month: 1.73 K
- Host name: 172.65.185.109
- IP address: 172.65.185.109
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ermium Therapeutics"
Ermium Therapeutics - Crunchbase Company Profile
Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The …See details»
Ermium Therapeutics - LinkedIn
Ermium Therapeutics is a discovery stage Biotechnology company developping innovative therapies for auto-immune diseasesSee details»
Ermium Therapeutics 2025 Company Profile: Valuation, Funding ...
Ermium Therapeutics General Information Description. Developer of a biotechnology platform designed for the treatment of autoimmune inflammatory diseases. The company's platform …See details»
ERMIUM THERAPEUTICS - Domain Therapeutics Group
Ermium therapeutics In 2019, Domain Therapeutics, invested €3M ($3.2M) in Ermium Therapeutics. Founded in June 2019 by Dr Jean-Philippe Herbeuval, Kurma Partners, Idinvest …See details»
ERMIUM THERAPEUTICS Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ERMIUM THERAPEUTICS of PARIS 5, ILE DE FRANCE. Get the latest business insights from Dun & …See details»
Ermium Therapeutics - Overview, News & Similar companies
Feb 2, 2022 Ermium Therapeutics Extends Its Initial €6,3 M Funding to €12,3 M to Further Advance Breakthrough Auto-Immune Disease Therapeutics PARIS--(BUSINESS WIRE)- …See details»
Ermium Therapeutics - Craft
Ermium Therapeutics has 5 employees across 2 locations. See insights on Ermium Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M …
Paris, France, June 30th 2022 - Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the …See details»
Ermium Therapeutics Company Information - Funding, Investors, …
Ermium Therapeutics, based in Paris, shows strong potential in developing treatments for autoimmune diseases. Operating on a B2B model, the company collaborates with biotech and …See details»
Ermium Therapeutics - Products, Competitors, Financials, …
Ermium Therapeutics is a biotechnology company focused on developing innovative therapies for auto-immune diseases. Use the CB Insights Platform to explore Ermium Therapeutics's full …See details»
Ermium Therapeutics Announces the Formation of a Scientific …
Feb 3, 2022 About Ermium Therapeutics Ermium Therapeutics, a Paris-based company, was founded in June 2019 by Jean-Philippe Herbeuval, Kurma Partners, Domain Therapeutics and …See details»
Ermium Therapeutics SAS - Drug pipelines, Patents, Clinical trials ...
Explore Ermium Therapeutics SAS with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 5 news, Disease Domain:Immune System Diseases, Technology Platform:Small …See details»
Ermium Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Ermium Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Ermium Therapeutics company information, funding & investors
Jun 1, 2019 Ermium Therapeutics, developing innovative therapies for auto-immune diseases, based on a breakthrough discovery. Here you'll find information about their funding, investors …See details»
Ermium Therapeutics Extends Its Initial €6,3 M Funding to €12,3 M …
Jun 30, 2022 Ermium Therapeutics Joël Crouzet, PhD, CEO [email protected] Ulysse Communications – Press Relations Tel: +33 (0) 6 87 88 47 26 Bruno Arabian …See details»
Ermium Therapeutics - Funding, Financials, Valuation & Investors
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. ...See details»
Ermium Therapeutics Fights Autoimmune Disease with Rare …
Oct 18, 2019 Ermium raised a Series A round of €6.3M last month to fund the development of its drugs, and is still in the stage of deciding which autoimmune condition to target first. The …See details»
Domain Therapeutics invests in Ermium Therapeutics to develop …
Descartes University). Ermium’s molecules are the first that are able to target a newly identified active area on the CXCR4 receptor to inhibit the overproduction of inflammatory cytokines, …See details»
Ermium Therapeutics extends its initial €6.3 M funding to €12.3 M …
Jun 30, 2022 Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding …See details»
Ethereum Foundation's Management and Board Structure
Apr 28, 2025 The recent appointments of the two Co-Executive Directors and President are part of a broader effort to strengthen the Ethereum Foundation, and this structure is designed to …See details»